EX-99.1 2 d944376dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Kestra Medical Technologies Reports Preliminary Second Quarter Fiscal 2026 Financial Results KIRKLAND, Wash., December 1, 2025 (GLOBE NEWSWIRE) - Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today reported preliminary financial results for the second quarter fiscal 2026 ended October 31, 2025. “Revenue is expected to grow by over 50% in the second quarter and continues to exceed our FY26 plan, reflecting sustained commercial momentum as Kestra grows and penetrates the wearable defibrillator market,” said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. “In addition to our commercial execution, we are encouraged by the meaningful improvement in our gross margin, a result of the attractive unit economics and positive leverage inherent in our business model.” Preliminary Second Quarter Fiscal 2026 Financial Results Revenue is expected to be $22.2 to $22.6 million, an increase of 52% at the midpoint compared to $14.7 million in the prior year period. Gross profit is expected to be $11.0 to $11.4 million compared to …
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Kestra Medical Technologies, Ltd.
KMTSNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On December 1, 2025, Kestra Medical Technologies, Ltd. (the “Company”) issued a press release announcing certain selected preliminary estimated financial results for the fiscal quarter ended October 31, 2025. A copy of the press release, dated December 1, 2025, is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.…
Company context
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S. The ASSURE WCD automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient’s heart to normal rhythm. The ASSURE WCD was purpose-built to enhance patient comfort and compliance and directly address the key barriers to adoption associated with the only other commercially available WCD. We believe the ASSURE WCD offers significant clinical and functional advantages, including greater patient compliance as a result of a major reduction in false alarms, enhanced comfort and wearability. In addition to the ASSURE WCD, our Cardiac Recovery System platform includes a comprehensive suite of fully integrated digital soluti